Caption Management’s Relmada Therapeutics RLMD Stock Holding History

Caption Management’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-5,889	Closed	-$189K	–	1758
2021 Q2	$189K	Hold	5,889	–	–	﹤0.01%	1181
2021 Q1	$208K	Buy	+5,889	New	+$206K	﹤0.01%	913

Other funds holding RLMD

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

SSC

Spruce Street Capital New York $416M AUM

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Caption Management's RLMD Position: Q3 2021 in Review

Caption Management sold out of Relmada Therapeutics (RLMD) in Q3 2021, closing a stake of 5,889 shares — an estimated $189K sold.

Caption Management first reported a position in RLMD in Q1 2021 and held it in 2 quarters. The position peaked at $208K in Q1 2021. 87 funds tracked by Wall St. Rank hold RLMD as of Q3 2021.

Caption Management reported no remaining Relmada Therapeutics position as of Q3 2021 after selling out during the quarter.
Caption Management sold 5,889 Relmada Therapeutics shares in Q3 2021, an estimated $189K.
Caption Management first reported a position in Relmada Therapeutics in Q1 2021 and held it in 2 quarters.
Caption Management's Relmada Therapeutics position peaked at $208K in Q1 2021.
87 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2021.

Based on Caption Management's 13F filing for Q3 2021, filed 12 Nov 2021.